Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
The Candel Therapeutics, Inc. (CADL) news page on Stock Titan aggregates company-issued updates, press releases, and related coverage focused on its multimodal viral immunotherapy programs in oncology. Candel describes itself as a clinical-stage biopharmaceutical company developing off-the-shelf biological immunotherapies based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, with lead candidates CAN-2409 and CAN-3110 in solid tumors.
Visitors to this page can follow announcements about clinical trial progress, including pivotal and phase 2 studies of CAN-2409 in intermediate-to-high-risk localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC), as well as phase 1b data for CAN-3110 in recurrent high-grade glioma. Candel’s releases also highlight regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug Designation granted by the U.S. Food and Drug Administration for specific indications.
News items frequently cover scientific presentations at major conferences, including ASTRO, ASCO, and the Society for Immunotherapy of Cancer (SITC), where Candel discusses subgroup analyses, biomarker findings, and multi-omics data related to its viral immunotherapy approach. Additional updates describe financing transactions, such as equity offerings and a term loan facility, as well as corporate developments like research advisory board appointments and investor conference participation.
By reviewing the CADL news feed, investors and researchers can see how Candel communicates the evolution of its CAN-2409 and CAN-3110 programs, the role of the enLIGHTEN™ Discovery Platform, and key milestones disclosed in its own press releases and referenced in SEC filings. Bookmark this page to access a centralized view of Candel’s publicly released information on its oncology-focused pipeline and corporate activities.
Candel Therapeutics (CADL) reported Q3 2024 financial results with a net loss of $10.6 million compared to $8.4 million in Q3 2023. Research and development expenses decreased to $5.4 million from $5.8 million year-over-year, while general and administrative expenses increased to $3.3 million from $3.0 million. The company's cash position stands at $16.6 million, expected to fund operations through Q1 2025.
The company remains on track for two key clinical trial readouts in Q4 2024: topline disease-free survival data from the phase 3 trial of CAN-2409 in intermediate/high-risk prostate cancer and topline progression-free survival data from the phase 2b trial in low/intermediate risk prostate cancer. Additionally, promising clinical data was reported for CAN-3110 in recurrent high-grade glioma, with 3 out of 6 patients surviving over one year.
Candel Therapeutics (Nasdaq: CADL), a clinical stage biopharmaceutical company developing biological immunotherapies for cancer treatment, has announced its participation in the Jefferies London Healthcare Conference 2024.
The company's President and CEO, Paul Peter Tak, will deliver a presentation on Wednesday, November 20, 2024, from 9:30-9:55AM GMT / 4:30-4:55AM EST. The presentation will be accessible via webcast, with a replay available for up to 90 days on the company's website under the Investors section.
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cell lines and in vivo murine melanoma models. The therapy's effectiveness is linked to Nestin expression in cancer cells and specific genetic alterations. The data showed tumor-specific cytotoxicity with dose-dependent inhibition of tumor growth and regression in some cases. The treatment was well-tolerated and associated with systemic immune activation, similar to effects observed in high-grade glioma patients.
Candel Therapeutics presented three key developments at the 16th Annual International Oncolytic Virotherapy Conference. The highlights include promising data from the CAN-3110 phase 1b trial in recurrent high-grade glioma, showing 3 out of 6 patients surviving over one year after treatment. The trial demonstrated improved survival compared to historical controls, with survival times of 12.2, 13.0, and 18.7 months.
The company also showcased a new multimodal immunotherapy candidate featuring IL-12 and IL-15, which showed significant tumor growth inhibition. Additionally, biopsy analysis revealed dense lymphocyte infiltrates and minimal tumor cells post-treatment, suggesting effective immune system activation.
Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, announced its upcoming presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas, and virtually.
The company will present a poster titled 'Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma'. Dr. Anne Diers, Senior Director of Research at Candel Therapeutics, will present the abstract numbered 995 on Friday, November 8, 2024, in the Exhibit Halls A and B of the George R. Brown Convention Center.
Additional details from the presentation will be made available on Candel's website following the event.
Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will be held both in-person and virtually from September 9-11, 2024.
Key details:
- Presenter: Paul Peter Tak, MD, PhD, FMedSci, Candel's President and CEO
- Date: Monday, September 9, 2024
- Time: Available from 7:00 a.m. ET onwards
- Webcast link provided for virtual attendance
The presentation will be accessible through the company's website, with a replay available for up to 90 days after the event.
Candel Therapeutics (Nasdaq: CADL) reported its Q2 2024 financial results and recent corporate highlights. Key developments include:
1. Positive survival data from phase 2 trials of CAN-2409 in pancreatic cancer and non-small cell lung cancer (NSCLC).
2. FDA orphan drug designations for CAN-2409 and CAN-3110 in pancreatic cancer and recurrent high-grade glioma, respectively.
3. Inclusion in the Russell 3000 Index.
4. Q2 2024 net loss of $22.2 million, compared to $9.6 million in Q2 2023.
5. Cash position of $21.5 million as of June 30, 2024, expected to fund operations into Q1 2025.
The company anticipates key data readouts in Q4 2024 for its prostate cancer trials.
Candel Therapeutics, a clinical stage biopharmaceutical company, will participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. The event is scheduled for June 25, 2024 at 3:00 p.m. ET. Paul Peter Tak, the President and CEO, will engage in a fireside chat. A live webcast will be available on the company's website under the News & Events section and will be archived for 90 days.
Candel Therapeutics (CADL) announced its inclusion in the Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective July 1, 2024. This inclusion signifies recognition of Candel’s market capitalization and progress in its clinical programs focused on multimodal biological immunotherapies for cancer. Membership in the Russell 3000 Index means automatic inclusion in either the Russell 1000 or Russell 2000 Index, and other relevant style indexes. The Russell US Indexes, maintained by FTSE Russell, are key benchmarks with approximately $10.5 trillion in assets benchmarked against them as of December 2023.
CEO Paul Peter Tak, MD, PhD, emphasized that this inclusion will increase visibility among investors and enhance engagement with the investment community, supporting Candel’s mission to develop novel immunotherapies for unmet medical needs.
The FDA has granted Orphan Drug Designation to CAN-3110, Candel Therapeutics' oncolytic viral immunotherapy for treating recurrent high-grade glioma (rHGG). This designation offers developmental incentives and up to 7 years of U.S. market exclusivity upon approval. Previously, CAN-3110 received Fast Track Designation for rHGG. The company is conducting a multi-institutional Phase 1b clinical trial, with initial results indicating strong anti-tumoral responses and extended survival. Candel will present further data on CAN-3110's feasibility and safety at the 2024 ASCO Annual Meeting. CEO Paul Peter Tak emphasized the potential of CAN-3110 and the company's commitment to developing effective treatments for rHGG.